Literature DB >> 20974962

FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo.

Falk Nimmerjahn1, Anja Lux, Heike Albert, Melissa Woigk, Christian Lehmann, Diana Dudziak, Patrick Smith, Jeffrey V Ravetch.   

Abstract

Cellular Fcγ receptors are essential for IgG-dependent effector functions in vivo. There is convincing evidence that selective activating Fcγ receptors are responsible for the activity of individual IgG subclasses. Thus, IgG1 activity is absent in FcγRIII-deficient mice, and several studies suggest that the activity of the most potent IgG subclasses, IgG2a and IgG2b, might be dependent on either individual or a combination of activating FcγRs. To study the role of individual activating FcγRs for IgG subclass activity, we generated an FcγRIV-deficient mouse and showed that a variety of IgG2a- and IgG2b-dependent effector functions are impaired in the absence of this activating Fc receptor in models of autoimmunity and antibody-dependent cellular cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974962      PMCID: PMC2984189          DOI: 10.1073/pnas.1014515107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

Review 1.  Antibody-mediated modulation of immune responses.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

Review 2.  Fcgamma receptors as regulators of immune responses.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

3.  Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies.

Authors:  Angela Giorgini; Heather J Brown; Helen R Lock; Falk Nimmerjahn; Jeffrey V Ravetch; J Sjef Verbeek; Steven H Sacks; Michael G Robson
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

4.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

5.  Both FcgammaRIV and FcgammaRIII are essential receptors mediating type II and type III autoimmune responses via FcRgamma-LAT-dependent generation of C5a.

Authors:  Shahzad N Syed; Stephanie Konrad; Kristina Wiege; Bernhard Nieswandt; Falk Nimmerjahn; Reinhold E Schmidt; J Engelbert Gessner
Journal:  Eur J Immunol       Date:  2009-12       Impact factor: 5.532

6.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

7.  Arthritis critically dependent on innate immune system players.

Authors:  Hong Ji; Koichiro Ohmura; Umar Mahmood; David M Lee; Frans M A Hofhuis; Susan A Boackle; Kazue Takahashi; V Michael Holers; Mark Walport; Craig Gerard; Alan Ezekowitz; Michael C Carroll; Michael Brenner; Ralph Weissleder; J Sjef Verbeek; Veronique Duchatelle; Claude Degott; Christophe Benoist; Diane Mathis
Journal:  Immunity       Date:  2002-02       Impact factor: 31.745

8.  Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice.

Authors:  Lucie Baudino; Falk Nimmerjahn; Samareh Azeredo da Silveira; Eduardo Martinez-Soria; Takashi Saito; Michael Carroll; Jeffrey V Ravetch; J Sjef Verbeek; Shozo Izui
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

9.  Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV.

Authors:  Marielle A Otten; Gerben J van der Bij; Sjef J Verbeek; Falk Nimmerjahn; Jeffrey V Ravetch; Robert H J Beelen; Jan G J van de Winkel; Marjolein van Egmond
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

10.  Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III.

Authors:  L Fossati-Jimack; A Ioan-Facsinay; L Reininger; Y Chicheportiche; N Watanabe; T Saito; F M Hofhuis; J E Gessner; C Schiller; R E Schmidt; T Honjo; J S Verbeek; S Izui
Journal:  J Exp Med       Date:  2000-04-17       Impact factor: 14.307

View more
  73 in total

1.  Unlocking the bone: Fcγ-receptors and antibody glycosylation are keys to connecting bone homeostasis to humoral immunity.

Authors:  Michaela Seeling; Falk Nimmerjahn
Journal:  Ann Transl Med       Date:  2015-07

Review 2.  The Role and Function of Fcγ Receptors on Myeloid Cells.

Authors:  Stylianos Bournazos; Taia T Wang; Jeffrey V Ravetch
Journal:  Microbiol Spectr       Date:  2016-12

3.  Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.

Authors:  Julien Ratelade; Nithi Asavapanumas; Alanna M Ritchie; Scott Wemlinger; Jeffrey L Bennett; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

4.  Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases.

Authors:  Dipti Vijayan; Deborah S Barkauskas; Kimberley Stannard; Erin Sult; Rebecca Buonpane; Kazuyoshi Takeda; Michele W L Teng; Kris Sachsenmeier; Carl Hay; Mark J Smyth
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

5.  Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways.

Authors:  Polina Weitzenfeld; Stylianos Bournazos; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

6.  Fcγ receptor III and Fcγ receptor IV on macrophages drive autoimmune valvular carditis in mice.

Authors:  Patricia M Hobday; Jennifer L Auger; Gregory R Schuneman; Stefanie Haasken; J Sjef Verbeek; Bryce A Binstadt
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

7.  Immune complexes regulate bone metabolism through FcRγ signalling.

Authors:  Takako Negishi-Koga; Hans-Jürgen Gober; Eriko Sumiya; Noriko Komatsu; Kazuo Okamoto; Shinichiro Sawa; Ayako Suematsu; Tomomi Suda; Kojiro Sato; Toshiyuki Takai; Hiroshi Takayanagi
Journal:  Nat Commun       Date:  2015-03-31       Impact factor: 14.919

8.  A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors.

Authors:  Maddalena Arigoni; Giuseppina Barutello; Stefania Lanzardo; Dario Longo; Silvio Aime; Claudia Curcio; Manuela Iezzi; Yujuan Zheng; Irmeli Barkefors; Lars Holmgren; Federica Cavallo
Journal:  Angiogenesis       Date:  2012-03-17       Impact factor: 9.596

9.  A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.

Authors:  Natalie L M Ramsey; Maria Visciano; Richard Hunte; Lip Nam Loh; Clare Burn Aschner; William R Jacobs; Betsy C Herold
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

10.  Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.

Authors:  Fernando Souza-Fonseca-Guimaraes; Stephen J Blake; Amani Makkouk; Cariad Chester; Holbrook E Kohrt; Mark J Smyth
Journal:  Oncoimmunology       Date:  2016-06-30       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.